Evidence map›Paper›PMID 40987397›Full record

ArticleJournal of advanced research2026

Integrative epitranscriptomic and transcriptomic characterization in human colorectal cancer.

Ting Gong, Sudhir Kumar Rai, Yong Zhu, Yutong Wang, Yu Chen, Li Ma, Xiaomou Wei, Zhougui Ling, Asmita Pandey, Yujia Qin and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ting GongDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Sudhir Kumar RaiDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA; Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Yong ZhuNational Medical Centre of Colorectal Disease, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210001, China.
Yutong WangSchool of Public Health, Qilu Medical University, Zibo 255314 Shandong Province, China.
Yu ChenDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Li MaDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Xiaomou WeiClinical Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545000, China.
Zhougui LingDepartment of Pulmonary and Critical Care Medicine, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China.
Asmita PandeyDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Yujia QinDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Matthew HuoDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Mayumi JijiwaDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Masaki NasuDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Zao ZhangDepartment of Medicine the Queen's Medical Center, Honolulu, HI 96813, USA.
Shaoqiu ChenDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Zitong GaoDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Xiamin HuCollege of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Ken NakastuDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Hua YangDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Yuanyuan FuDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA.
Lang WuCancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Gang HuangShanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China. Electronic address: huangg@sumhs.edu.cn.
Peiwen FeiCancer Biology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA. Electronic address: pfei@cc.hawaii.edu.
Youping DengDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96813, USA; Genomics and Bioinformatics Shared Resource, University of Hawaii Cancer Center, Honolulu, HI 96813, USA. Electronic address: dengy@hawaii.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite significant progress in understanding the molecular basis of colorectal cancer (CRC), the precise mechanisms driving its development and progression remain poorly defined. This gap limits the identification of novel therapeutic targets and the development of effective early detection methods. N6-methyladenosine (m6A) has merged as a key role in CRC pathogenesis. But research on mRNA methylation in CRC remains sparse.

objectivesWe aimed to address the roles of m6A modifications in CRC and to understand how mRNA methylation contributes to CRC development and progression.

methodsWe obtained a comprehensive mapping of altered m6 peaks within mRNAs using Methylated RNA Immunoprecipitation Sequencing (MeRIP-seq) from 34 CRC samples and 34 adjacent normal tissue samples and dissect molecular mechanisms of identified key CRC gene(s). By integrating these data, we identified differentially expressed mRNAs with altered m6A levels. Further analysis identified 119 overlapping peaks with both significantly altered RNA methylation and expression levels. Finally, we analyzed the relationship between m6A-regulated gene expression and Immune infiltrates using CRC patient-derived PBMC samples. Additionally, we established a subcutaneous xenograft tumor model to explore the role of SIM2 in CRC progression.

resultsOur comprehensive analysis of 68 fresh-frozen CRC samples identified 119 overlapping m6A peaks across 77 genes, classified based on m6A and mRNA expression changes. Survival analyses revealed a signature of m6A-modified genes with prognostic potential. These methylated genes were significant associated with immune cell profiles in the tumor microenvironment and immune checkpoints regulation, highlighting m6A as a promising immunotherapeutic target for CRC. SIM2 emerged as a key candidate, exhibiting elevated m6A and RNA expression levels in tumors and Macrophage M2 cells. NTMT1 (a writer) and YTHDF1 (a reader) were identified as pivotal regulators of m6A modifications in the 5'-UTR of SIM2 mRNA, emphasizing their role in CRC progression. Silencing methylated SIM2 significantly suppressed tumor growth, suggesting its potential as a therapeutic target.

conclusionOur integrative analyses provide a valuable resource for unraveling the molecular landscape of CRC. These finding offer new insight for advancing diagnostic precision and refining prognostic and therapeutic strategies for CRC.

Indexed as

Colorectal NeoplasmsEpitranscriptomeGene Expression Regulation, NeoplasticTranscriptomeAdenosineAnimalsCell Line, TumorEpitranscriptomicsFemaleGene Expression ProfilingHumansMaleMiceRNA, MessengerRNA MethylationAdenosineN-methyladenosineRNA, MessengerColorectal cancerDiagnosisImmunotherapym6A modificationSingle-minded 2, NTMT1Survival outcome

Identifiers

PMID40987397
PMCPMC13227294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.